文献速递癫痫

增强谷氨酸摄取作为新型抗癫痫方法:临床前概念验证

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept.
PubMed 文献 · Ann Neurol · 2024-11-08

该研究在多种急性与慢性癫痫动物模型中评估了谷氨酸摄取正向变构调节剂(R)-AS-1的保护作用,并在标准测试中评估其不良反应。结果显示(R)-AS-1在多种模型中具有稳健保护作用且耐受性良好,并可在体外增强谷氨酸摄取,该效应可被EAAT2选择性抑制剂WAY 213613逆转。作者认为变构增强EAAT2功能可能为癫痫及谷氨酸兴奋性毒性相关神经系统疾病提供新治疗策略。

要点

  • (R)-AS-1在最大电休克、6 Hz诱发发作、角膜点燃、内侧颞叶癫痫等多种动物模型中显示稳健保护作用。
  • (R)-AS-1在转棒、最小运动损伤和Irwin测试中显示良好的不良反应特征。
  • (R)-AS-1在体外增强谷氨酸摄取且该效应可被WAY 213613逆转,重复给药后体内GLT-1表达未见影响。

核心结论

  • (R)-AS-1耐受性良好,并在临床前对癫痫发作提供稳健疗效。
  • 变构增强EAAT2功能可能为癫痫及潜在其他谷氨酸兴奋性毒性相关神经系统疾病提供新型治疗策略。

研究设计与样本

  • 在多种急性与慢性癫痫动物模型中评估(R)-AS-1,并在啮齿类标准测试中评估其不良反应特征。
  • 在表达转运体的COS-7细胞中评估(R)-AS-1对谷氨酸摄取的影响,并使用选择性竞争性EAAT2抑制剂WAY 213613探究增强摄取的逆转。
  • 采用共聚焦显微镜和Western blotting分析研究(R)-AS-1对小鼠GLT-1表达的潜在影响。

主要发现

  • (R)-AS-1在最大电休克和6 Hz诱发发作、角膜点燃、内侧颞叶癫痫、拉莫三嗪抵抗性杏仁核点燃以及匹罗卡品或Theiler鼠脑脊髓炎病毒诱发的发作中显示稳健保护。
  • (R)-AS-1在转棒、最小运动损伤和Irwin测试中显示良好的不良反应特征。
  • (R)-AS-1在体外增强谷氨酸摄取,该效应可被WAY 213613消除,重复治疗后体内GLT-1表达未见影响。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Excitotoxicity is a common hallmark of epilepsy and other neurological diseases associated with elevated extracellular glutamate levels. Thus, here, we studied the protective effects of (R)-AS-1, a positive allosteric modulator (PAM) of glutamate uptake in epilepsy models. METHODS: (R)-AS-1 was evaluated in a range of acute and chronic seizure models, while its adverse effect profile was assessed in a panel of standard tests in rodents. The effect of (R)-AS-1 on glutamate uptake was assessed in COS-7 cells expressing the transporter. WAY 213613, a selective competitive EAAT2 inhibitor, was used to probe the reversal of the enhanced glutamate uptake in the same transporter expression system. Confocal microscopy and Western blotting analyses were used to study a potential influence of (R)-AS-1 on GLT-1 expression in mice. RESULTS: (R)-AS-1 showed robust protection in a panel of animal models of seizures and epilepsy, including the maximal electroshock- and 6 Hz-induced seizures, corneal kindling, mesial temporal lobe epilepsy, lamotrigine-resistant amygdala kindling, as well as seizures induced by pilocarpine or Theiler's murine encephalomyelitis virus. Importantly, (R)-AS-1 displayed a favorable adverse effect profile in the rotarod, the minimal motor impairment, and the Irwin tests. (R)-AS-1 enhanced glutamate uptake in vitro and this effect was abolished by WAY 213613, while no influence on GLT-1 expression in vivo was observed after repeated treatment. INTERPRETATION: Collectively, our results show that (R)-AS-1 has favorable tolerability and provides robust preclinical efficacy against seizures. Thus, allosteric enhancement of EAAT2 function could offer a novel therapeutic strategy for treatment of epilepsy and potentially other neurological disorders associated with glutamate excitotoxicity. ANN NEUROL 2025;97:344-357.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Kamiński K, Socała K, Abram M, et al. Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept. Ann Neurol. 2024. PMID: 39512205. doi:10.1002/ana.27124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。